Vmbook Online ordering

Ophthotech Corporation

Sure, I'll be happy to help!

OPHT stands for Ophthalmology, and it is a publicly traded company that specializes in developing a pipeline of innovative ophthalmic products.

Here are some key statistics for OPHT:

- Market Capitalization: 342.29 million USD

- Current share price: 4.28 USD

- P/E ratio: -2.63

- EPS (ttm): -0.05

- Income Growth Rate: -38.10%

- Revenue Growth Rate: 62.50%

It's critical to remember that stock prices can change fast and that this data may not be current. For the most up-to-date information, always check current stock prices and financial data.

OPHT specializes in opthamology. Its key products are DEXYCU and YUTIQ. DEXYCU intraocular lens (IOL) is used in catract surgery to reduce the need for glasses after surgery. YUTIQ is a treartment for chronic noninfectious uveitis affecting the back of the eye, causing long-term vision problems, including blindness, if left untreated. YUTIQ is designed to lessen the frequency of office visits as part of a patient's uveitis treatment regimen.

Financial Report for Third Quarter 2022:

- Revenue: $16.4 million

- Net Loss: Approximately $14.5 million

- DEXYCU IOL sale: Over 7,700 lenses in the third quarter 2022, a 30% increase year-over-year.

Financial Report for Full Year 2022:

- Net revenue: $66.7 million

- Net loss: Approximately $47.4 million

- DEXYCU IOL sales: 27,142 lenses, a 38% year-over-year increase.

Ophthalmology's stock price has been volatile due to the company's financial performance and market expectations. The corporation has made significant investments in new medicine development and commercialization, which has impacted recent earnings.

However, analysts expect the company's prospects to be positive due to its promising drug pipeline and dedication to ophthalmology research and development.

You should conduct further study and seek guidance from a financial professional before deciding on investing in the stock market.